Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted): 2022-2025
Historic EPS (Weighted Average and Diluted) for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$1.06.
- Entrada Therapeutics' EPS (Weighted Average and Diluted) fell 202.86% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.56, marking a year-over-year decrease of 260.00%. This contributed to the annual value of $1.68 for FY2024, which is 940.00% up from last year.
- As of Q3 2025, Entrada Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.06, which was down 1.92% from -$1.04 recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' EPS (Weighted Average and Diluted) registered a high of $1.55 during Q2 2024, and its lowest value of -$1.06 during Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.28 (recorded in 2023), while the average stood at -$0.08.
- In the last 5 years, Entrada Therapeutics' EPS (Weighted Average and Diluted) spiked by 423.81% in 2024 and then crashed by 202.86% in 2025.
- Quarterly analysis of 4 years shows Entrada Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.78 in 2022, then spiked by 64.10% to -$0.28 in 2023, then surged by 85.71% to -$0.04 in 2024, then slumped by 202.86% to -$1.06 in 2025.
- Its last three reported values are -$1.06 in Q3 2025, -$1.04 for Q2 2025, and -$0.42 during Q1 2025.